1. |
丁福全, 王在国. 肝癌复发转移的临床研究进展. 中国实用外科杂志, 2000, 20(3): 174-175.
|
2. |
Nakayama H, Takayama T. Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. World J Hepatol, 2015, 7(2): 261-269.
|
3. |
中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版). 临床肝 胆病杂志, 2017, 33(8): 1419-1431.
|
4. |
陈延宇, 张晓赟, 李川, 等. 复发性肝细胞癌的外科治疗现状与进展. 华西医学, 2019, 34(6): 688-692.
|
5. |
林鹏, 蔡敏清, 房俊伟, 等. 肝癌术后复发的外科治疗研究现状及进展. 器官移植, 2022, 13(1): 111-119.
|
6. |
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 2022, 76(3): 681-693.
|
7. |
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology, 2011, 53(3): 1020-1022.
|
8. |
国家科技部传染病防治重大专项课题《病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究》专家组. 肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版). 中国实用外科杂志, 2021, 41(1): 20-30.
|
9. |
Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg, 2017, 104(11): 1433-1442.
|
10. |
中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 原发性肝癌局部消融治疗的专家共识. 临床肿瘤学杂志, 2011, 16(1): 70-73.
|
11. |
Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med, 2021, 15(2): 155-169.
|
12. |
蒋经柱, 李浩权, 王在国, 等. 免疫联合靶向方案治疗晚期肝癌临床研究. 中国肿瘤外科杂志, 2022, 14(2): 120-126.
|
13. |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 2018, 391(10126): 1163-1173.
|
14. |
Lim H, Ramjeesingh R, Liu D, et al. Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: A systematic review. J Natl Cancer Inst, 2021, 113(2): 123-136.
|
15. |
Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol, 2018, 19(7): 940-952.
|
16. |
Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature, 2019, 567(7747): 257-261.
|
17. |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.
|
18. |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1): 25-34.
|
19. |
Facciorusso A, Abd El Aziz MA, Sacco R. Efficacy of regorafenib in hepatocellular carcinoma patients: A systematic review and meta-analysis. Cancers (Basel), 2019, 12(1): 36. doi: 10.3390/cancers12010036.
|
20. |
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 389(10064): 56-66.
|